What Researchers Did
Researchers reported a rare case of combined central retinal artery and vein occlusion in a patient with Factor V Leiden mutation treated with hyperbaric oxygen therapy.
What They Found
A 49-year-old woman with combined central retinal artery and vein occlusion and Factor V Leiden mutation initially improved from a best corrected visual acuity (BCVA) of 1/20 to 10/10 after hyperbaric oxygen therapy. However, her vision later declined to <1/20 due to a new central retinal vein occlusion, eventually stabilizing at 6/10 after bevacizumab injections.
What This Means for Canadian Patients
Canadian patients experiencing sudden vision loss from combined retinal artery and vein occlusion, especially younger individuals, may benefit from thorough investigation for underlying conditions like thrombophilic disorders. Early diagnosis and tailored treatment, potentially including hyperbaric oxygen therapy or anti-VEGF injections, could help manage this severe condition.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
As a single case report, the findings of this study cannot be generalized to a broader patient population.